Insider Selling: Takeda Pharmaceutical (NYSE:TAK) Insider Sells $813,720.60 in Stock

Takeda Pharmaceutical Co. (NYSE:TAK) insider Lauren Rusckowski Duprey sold 47,586 shares of the company’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $17.10, for a total value of $813,720.60. Following the sale, the insider owned 226,057 shares in the company, valued at approximately $3,865,574.70. This trade represents a 17.39% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Takeda Pharmaceutical Stock Down 0.3%

Shares of TAK stock traded down $0.06 during trading hours on Wednesday, reaching $17.42. 2,004,364 shares of the stock were exchanged, compared to its average volume of 4,402,927. Takeda Pharmaceutical Co. has a 12-month low of $12.99 and a 12-month high of $18.90. The business’s fifty day moving average is $16.49 and its two-hundred day moving average is $17.13. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.14 and a quick ratio of 0.62. The firm has a market capitalization of $55.82 billion, a P/E ratio of 51.24 and a beta of -0.08.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $0.56 earnings per share for the quarter. The business had revenue of $6.90 billion for the quarter. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. As a group, research analysts expect that Takeda Pharmaceutical Co. will post 3.01 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently weighed in on TAK. Wall Street Zen raised Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Saturday, July 18th. Zacks Research raised shares of Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 4th. Finally, Weiss Ratings downgraded shares of Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, July 30th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold”.

Hedge Funds Weigh In On Takeda Pharmaceutical

Several hedge funds have recently made changes to their positions in the company. Arrowstreet Capital Limited Partnership increased its position in shares of Takeda Pharmaceutical by 100.9% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 5,682,847 shares of the company’s stock worth $88,596,000 after purchasing an additional 2,854,069 shares in the last quarter. UBS Group AG boosted its position in shares of Takeda Pharmaceutical by 46.4% in the 3rd quarter. UBS Group AG now owns 5,893,969 shares of the company’s stock valued at $86,288,000 after purchasing an additional 1,869,323 shares during the period. Qube Research & Technologies Ltd grew its stake in Takeda Pharmaceutical by 407.9% during the 3rd quarter. Qube Research & Technologies Ltd now owns 1,775,845 shares of the company’s stock worth $25,998,000 after buying an additional 1,426,184 shares during the last quarter. Van ECK Associates Corp grew its stake in Takeda Pharmaceutical by 98.4% during the 4th quarter. Van ECK Associates Corp now owns 2,305,397 shares of the company’s stock worth $35,941,000 after buying an additional 1,143,117 shares during the last quarter. Finally, Voloridge Investment Management LLC increased its position in Takeda Pharmaceutical by 1,070.7% during the fourth quarter. Voloridge Investment Management LLC now owns 962,502 shares of the company’s stock worth $15,005,000 after buying an additional 880,289 shares during the period. Hedge funds and other institutional investors own 9.17% of the company’s stock.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.